Phase 2a trial of atebimetinib + mGnP in first-line pancreatic cancer patients, well above the standard of care benchmark from GnP of 35% overall survival;On track for expanded pancreatic cancer cohor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results